162 related articles for article (PubMed ID: 12868147)
1. [Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?].
Parravicini M; Del Boca C
Arch Ital Urol Androl; 2003 Jun; 75(2):99-101. PubMed ID: 12868147
[TBL] [Abstract][Full Text] [Related]
2. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M
Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136
[TBL] [Abstract][Full Text] [Related]
3. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
4. [Early diagnosis of prostatic carcinoma by random biopsies in 60 patients clinically negative but with PSA greater than 8.9 ng/ml].
Bianchi A; Bottanelli A; Baroni G; Rovellini P; Sciaraffia G; Toia G; Marcelli G
Arch Ital Urol Androl; 1997 Dec; 69(5):313-8. PubMed ID: 9477617
[TBL] [Abstract][Full Text] [Related]
5. [Yield of ultrasonography-guided transrectal biopsy in the diagnosis of carcinoma of the prostate].
Fernández González I; Ruiz Rubio JL; Llorente Abarca C; Aramburu González JA; Montes Díaz MJ; Herrero Payo A; Sánchez Sánchez E; Berenguer Sánchez A
Arch Esp Urol; 1995; 48(6):587-94. PubMed ID: 7544968
[TBL] [Abstract][Full Text] [Related]
6. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography].
Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Gómez dos Santos V; García González R
Arch Esp Urol; 1997 May; 50(4):339-45. PubMed ID: 9313042
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
8. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
9. [Real-time elastography in the diagnosis of prostate cancer: personal experience].
Romagnoli A; Autieri G; Centrella D; Gastaldi C; Pedaci G; Rivolta L; Pozzi E; Anghileri A; Cerabino M; Bianchi CM; Roggia A
Urologia; 2010; 77(4):248-53. PubMed ID: 21234867
[TBL] [Abstract][Full Text] [Related]
10. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies.
Borboroglu PG; Comer SW; Riffenburgh RH; Amling CL
J Urol; 2000 Jan; 163(1):158-62. PubMed ID: 10604336
[TBL] [Abstract][Full Text] [Related]
11. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
12. [Role of rectal exploration, suprapubic and transrectal prostatic ultrasonography, and PSA in the diagnosis and follow-up of prostatic carcinoma].
Speranza I; Bianco V; Banci M; Muià R; Gianni W; Bacciu O; Vecchione A; Marchei P
Minerva Med; 1998; 89(7-8):267-75. PubMed ID: 9824988
[TBL] [Abstract][Full Text] [Related]
13. Saturation biopsy technique increase the capacity to diagnose adenocarcinoma of prostate in patients with PSA < 10 ng/ml, after a first negative biopsy.
Giulianelli R; Brunori S; Gentile BC; Vincenti G; Nardoni S; Pisanti F; Shestani T; Mavilla L; Albanesi L; Attisani F; Mirabile G; Schettini M
Arch Ital Urol Androl; 2011 Sep; 83(3):154-9. PubMed ID: 22184840
[TBL] [Abstract][Full Text] [Related]
14. [Our experience about utility of the prostate mapping (8 + 8 biopsy) in the diagnosis of prostate tumour].
Parravicini M; Del Boca C
Arch Ital Urol Androl; 2003 Jun; 75(2):102-4. PubMed ID: 12868148
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
16. [Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].
Yousra S; Rafik E; Manel M; Kacem M
Ann Biol Clin (Paris); 2010; 68(5):585-93. PubMed ID: 20870581
[TBL] [Abstract][Full Text] [Related]
17. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
19. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
[TBL] [Abstract][Full Text] [Related]
20. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
